Recent developments of interest in cardiovascular medicine
The GLP-1 receptor agonist dulaglutide (Trulicity) significantly reduced the primary composite endpoint of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke in top-line results released from the REWIND trial. Sponsor Eli Lilly touted it as the first cardiovascular outcomes trial to show superiority in a largely primary prevention population with type 2 diabetes.